Display options
Cite
Tomizawa M, Shinozaki F, Motoyoshi Y, et al. Cell death in a co-culture of hepatocellular carcinoma cells and human umbilical vascular endothelial cells in a medium lacking glucose and arginine. Oncol Lett. 2016;13(1):258-262doi: 10.3892/ol.2016.5454.
Tomizawa, M., Shinozaki, F., Motoyoshi, Y., Sugiyama, T., Yamamoto, S., & Ishige, N. (2017). Cell death in a co-culture of hepatocellular carcinoma cells and human umbilical vascular endothelial cells in a medium lacking glucose and arginine. Oncology letters, 13(1), 258-262. https://doi.org/10.3892/ol.2016.5454
Tomizawa, Minoru, et al. "Cell death in a co-culture of hepatocellular carcinoma cells and human umbilical vascular endothelial cells in a medium lacking glucose and arginine." Oncology letters vol. 13,1 (2017): 258-262. doi: https://doi.org/10.3892/ol.2016.5454
Tomizawa M, Shinozaki F, Motoyoshi Y, Sugiyama T, Yamamoto S, Ishige N. Cell death in a co-culture of hepatocellular carcinoma cells and human umbilical vascular endothelial cells in a medium lacking glucose and arginine. Oncol Lett. 2017 Jan;13(1):258-262. doi: 10.3892/ol.2016.5454. Epub 2016 Nov 30. PMID: 28123551; PMCID: PMC5245067.
Copy Download .nbib Format: NLM
Share it on

Oncol Lett. 2017 Jan;13(1):258-262. doi: 10.3892/ol.2016.5454. Epub 2016 Nov 30.

Cell death in a co-culture of hepatocellular carcinoma cells and human umbilical vascular endothelial cells in a medium lacking glucose and arginine.

Oncology letters

Minoru Tomizawa, Fuminobu Shinozaki, Yasufumi Motoyoshi, Takao Sugiyama, Shigenori Yamamoto, Naoki Ishige

Affiliations

  1. Department of Gastroenterology, National Hospital Organization Shimoshizu Hospital, Yotsukaido, Chiba 284-0003, Japan.
  2. Department of Radiology, National Hospital Organization Shimoshizu Hospital, Yotsukaido, Chiba 284-0003, Japan.
  3. Department of Neurosurgery, National Hospital Organization Shimoshizu Hospital, Yotsukaido, Chiba 284-0003, Japan.
  4. Department of Rheumatology, National Hospital Organization Shimoshizu Hospital, Yotsukaido, Chiba 284-0003, Japan.
  5. Department of Pediatrics, National Hospital Organization Shimoshizu Hospital, Yotsukaido, Chiba 284-0003, Japan.
  6. Department of Internal Medicine, National Hospital Organization Shimoshizu Hospital, Yotsukaido, Chiba 284-0003, Japan.

PMID: 28123551 PMCID: PMC5245067 DOI: 10.3892/ol.2016.5454

Abstract

Human primary hepatocytes are able to survive in a medium without glucose and arginine that is instead supplemented with galactose and ornithine (hepatocyte selection medium; HSM). This is because the cells produce glucose and arginine by the action of galactokinase (GALK) and ornithine carbamoyltransferase (OTC), respectively. It was expected that hepatocellular carcinoma (HCC) cells do not survive in HSM. In the current study, HCC cell lines (namely HLE, HLF, PLC/PRL/5, Hep3B and HepG2) and human umbilical vascular endothelial cells (HUVECs) were cultured in HSM, and the expression levels of GALK1, GALK2 and OTC were analyzed by reverse transcription-quantitative polymerase chain reaction. HLE, HLF and PLC/PRL/5 cells died on day 11, while Hep3B, HepG2 and HUVECs died on day 7. HLF cells were further analyzed as these cells had lower expression levels of GALK1, GALK2 and OTC compared with adult liver cells, and survived until day 11. In these cells, the expression levels of GALK1, GALK2 and OTC did not change on days 3 and 7 as compared to day 0. In addition, a co-culture of HLF cells with HUVECs was established and the medium was changed to HSM. It was observed that HLF cells and HUVECs in co-culture were damaged in HSM. In summary, HCC cells and HUVECs died in a medium without glucose and arginine that was supplemented with galactose and ornithine. HCC cells and HUVECs were damaged in HSM, suggesting a potential application for treatment with the medium.

Keywords: galactokinase; gluconeogenesis; ornithine carbamoyltransferase; urea cycle

References

  1. Neurol Res. 1994 Dec;16(6):460-4 - PubMed
  2. J Virol Methods. 2009 Nov;161(2):183-91 - PubMed
  3. J Cell Biol. 1972 Mar;52(3):559-68 - PubMed
  4. Diabetes Obes Metab. 2009 Sep;11(9):823-35 - PubMed
  5. Pathol Int. 1995 May;45(5):352-8 - PubMed
  6. Gut Liver. 2016 May 23;10 (3):332-9 - PubMed
  7. Metabolism. 2002 Jul;51(7):876-80 - PubMed
  8. Liver Cancer. 2014 Mar;3(1):9-17 - PubMed
  9. Cell Tissue Res. 2008 Jul;333(1):17-27 - PubMed
  10. Curr Pharm Des. 2008;14(11):1049-57 - PubMed
  11. Cell Physiol Biochem. 2000;10(1-2):37-55 - PubMed
  12. Biochem Biophys Res Commun. 2005 May 27;331(1):239-46 - PubMed
  13. Semin Intervent Radiol. 2013 Mar;30(1):3-11 - PubMed
  14. J Cancer Res Ther. 2009 Sep;5 Suppl 1:S2-6 - PubMed
  15. Int J Clin Exp Pathol. 2015 Nov 01;8(11):14383-91 - PubMed
  16. Biochem Biophys Res Commun. 1984 Aug 16;122(3):884-91 - PubMed
  17. Int J Clin Exp Med. 2015 Aug 15;8(8):13347-52 - PubMed
  18. Genomics. 1995 Jan 20;25(2):372-80 - PubMed
  19. Liver Cancer. 2014 May;3(2):119-24 - PubMed
  20. Genome Res. 1995 Aug;5(1):53-9 - PubMed
  21. Eur J Biochem. 2002 Feb;269(3):792-7 - PubMed
  22. Int J Mol Med. 2013 Feb;31(2):437-46 - PubMed
  23. PLoS One. 2013 Aug 14;8(8):e71897 - PubMed

Publication Types